TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
April 13, 2026
Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group
The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director....
February 5, 2026
Gilde Healthcare launches Climate Solutions fund realizing initial close at €250M
With commitments from international pension funds, banks, fund-of-funds, endowments and family offices, Gilde Healthcare realizes an initial close at €250 million Expansion into Climate Solutions builds on Gilde Healthcare’s track...
February 18, 2026
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
April 13, 2026
Filter & search
Fund strategy:
Loading...
These were all articles
0fa680ce28